266 related articles for article (PubMed ID: 35359844)
21. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.
Uchiyama AAT; Silva PAIA; Lopes MSM; Yen CT; Ricardo ED; Mutão T; Pimenta JR; Machado LM; Shimba DS; Peixoto RD
Curr Oncol; 2021 Feb; 28(1):783-799. PubMed ID: 33546228
[TBL] [Abstract][Full Text] [Related]
22. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
23. Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia.
Wu J; Dickinson S; Elgebaly Z; Blogg S; Heaney A; Soo Y; Daniels B; Weekes L
BMC Fam Pract; 2020 May; 21(1):85. PubMed ID: 32386520
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
Robinson M; Horn J
Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitors for chronic obstructive pulmonary disease.
Kikuchi S; Imai H; Tani Y; Tajiri T; Watanabe N
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013113. PubMed ID: 32844430
[TBL] [Abstract][Full Text] [Related]
26. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?
Abu-Amna M; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Mar; 83(3):545-550. PubMed ID: 30547192
[TBL] [Abstract][Full Text] [Related]
27. The effects of proton pump inhibitors on the microbiome in young children.
Levy EI; Hoang DM; Vandenplas Y
Acta Paediatr; 2020 Aug; 109(8):1531-1538. PubMed ID: 32027402
[TBL] [Abstract][Full Text] [Related]
28. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use.
Chowdhry M; Shah K; Kemper S; Zekan D; Carter W; McJunkin B
J Gastroenterol Hepatol; 2018 Oct; 33(10):1717-1721. PubMed ID: 29514412
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
Wedemeyer RS; Blume H
Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106
[TBL] [Abstract][Full Text] [Related]
30. Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy.
Kichenadasse G; Miners JO; Mangoni AA; Karapetis CS; Hopkins AM; Sorich MJ
J Natl Compr Canc Netw; 2021 May; 19(9):1037-1044. PubMed ID: 33951613
[TBL] [Abstract][Full Text] [Related]
31. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
Tjon JA; Pe M; Soscia J; Mahant S
Pharmacotherapy; 2013 Sep; 33(9):956-71. PubMed ID: 23712734
[TBL] [Abstract][Full Text] [Related]
33. Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Shamliyan TA; Middleton M; Borst C
Clin Ther; 2017 Feb; 39(2):404-427.e36. PubMed ID: 28189362
[TBL] [Abstract][Full Text] [Related]
34. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
[TBL] [Abstract][Full Text] [Related]
35. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M; Omarini C; Diodati L; Palleschi M; Meattini I; Crucitta S; Lorenzini G; Isca C; Fontana A; Livi L; Piacentini F; Fogli S; De Giorgi U; Danesi R
ESMO Open; 2021 Oct; 6(5):100231. PubMed ID: 34509802
[TBL] [Abstract][Full Text] [Related]
36. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations.
Koyyada A
Therapie; 2021; 76(1):13-21. PubMed ID: 32718584
[TBL] [Abstract][Full Text] [Related]
37. Repositioning of proton pump inhibitors in cancer therapy.
Lu ZN; Tian B; Guo XL
Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of lysosomal enzyme activities by proton pump inhibitors.
Liu W; Baker SS; Trinidad J; Burlingame AL; Baker RD; Forte JG; Virtuoso LP; Egilmez NK; Zhu L
J Gastroenterol; 2013 Dec; 48(12):1343-52. PubMed ID: 23478938
[TBL] [Abstract][Full Text] [Related]
39. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis.
Chang TE; Huang YS; Perng CL; Huang YH; Hou MC
J Chin Med Assoc; 2019 Oct; 82(10):756-761. PubMed ID: 31335628
[TBL] [Abstract][Full Text] [Related]
40. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy.
Ikemura K; Hiramatsu S; Okuda M
Front Pharmacol; 2017; 8():911. PubMed ID: 29311921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
